A new trial finds guselkumab is highly effective and well tolerated for moderate to severe scalp psoriasis in individuals ...

Guselkumab and risankizumab for psoriasis have the highest rates of drug survival among biologics measured and a comparable safety profile.

A new study published in the Journal of American Medical Association showed that Guselkumab was highly effective and durable ...

Discover a study that demonstrates the effectiveness of guselkumab in treating scalp psoriasis, offering significant symptom ...

Guselkumab improves scalp psoriasis and quality of life in patients with skin of color.

Guselkumab significantly improves psoriasis severity and quality of life compared with placebo in patients with skin of color.

Guselkumab, whether administered every 4 or 8 weeks, demonstrates “significant inhibition” of structural damage in patients with active psoriatic arthritis, according to data presented at the ...

Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2025. "Today’s strong results reflect the depth and strength of Johnson & Johnson’s uniquely diversified business operating ...

A new analysis highlights the effectiveness of risankizumab in patients with moderate plaque psoriasis and those newly classified as systemic therapy eligible under International Psoriasis Council ...

Despite recent significant advances in systemic therapies for psoriasis, topical treatment retains a prominent role for many patients. The American Academy of Dermatology/National Psoriasis ...

Psoriasis With a Side of Arthritis Biologics also represent the first choice of systemic therapy for Oyetewa Asempa, MD, of Baylor College of Medicine in Houston.

As summer began and temperatures rose in June, so too did TV ad spending for Novo Nordisk’s Wegovy. | As summer began and temperatures rose in June, so too did TV ad spending for Novo Nordisk’s Wegovy ...